Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 7/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27238433 | 0.90 | PDE4B (0.39) | PDE4BALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL30133093 | 0.87 | PDE4B (0.38) | PDE4BALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL30133161 | 0.85 | MAPT (0.40) | PDE4BALDH1A1TSHRMAPTTP53 | |
| SCHEMBL30133081 | 0.84 | PDE4B (0.40) | PDE4BALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL30133129 | 0.80 | SMN1; SMN2 (0.39) | ALDH1A1MEN1TSHRKMT2AMAPT | |
| SCHEMBL30133170 | 0.80 | PDE4B (0.38) | PDE4BALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL30133135 | 0.79 | SMN1; SMN2 (0.38) | PDE4BALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL29207749 | 0.78 | CXCR2 (0.46) | ALDH1A1MEN1TSHRKMT2AMAPT | |
| SCHEMBL30395831 | 0.76 | CNR2 (0.46) | PDE4BCXCR2 | |
| SCHEMBL27238434 | 0.76 | PDE4B (0.42) | PDE4BALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190889-A1 | NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4380940-A1 | NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023012130-A1 | NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190889-A1 | NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS | GABRA1, GABRA5, GABRB1 | PDE4B 231/4885ALDH1A1 911/4885MEN1 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.